Optimizing methotrexate use for the management of chronic pediatric non-infectious uveitis
优化甲氨蝶呤的使用以治疗慢性儿科非感染性葡萄膜炎
基本信息
- 批准号:10568202
- 负责人:
- 金额:$ 65.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-03-01 至 2028-02-29
- 项目状态:未结题
- 来源:
- 关键词:AdultAnteriorBiologicalBiological ProductsBiological Response Modifier TherapyBiometryBlindnessBlood specimenCellsChildChild HealthChildhoodChronicChronic Childhood ArthritisClinicalComplementCystoid Macular EdemaDataDecision MakingDiagnosisDiseaseDropsEnrollmentExtravasationEye diseasesFailureFluoresceinFluorescein AngiographyGene ExpressionGene Expression ProfileGene Expression ProfilingGenetic TranscriptionGlucocorticoidsGoalsImageImaging DeviceImmuneImmunologistImmunologyIndividualInflammationInflammatoryInvestigationLaboratoriesLocationMethotrexateModalityMonitorNomenclatureOphthalmologistOphthalmologyOptical Coherence TomographyOralOutcomePatient riskPatientsPharmaceutical PreparationsPrediction of Response to TherapyPredictive FactorResearchRheumatismRheumatologyRiskRisk FactorsSafetyStandardizationSystemic diseaseTestingTherapeuticTherapeutic EffectUnited States National Institutes of HealthUveitisVisionWhole BloodWorkanterior chamberclinical examinationdemographicsdesigndisease heterogeneityeffective therapyexperimental studyfollow-upgene discoveryhigh riskimaging modalityimprovedinnovationocular imagingophthalmic examinationperipheral bloodpersonalized medicinepredicting responsepredictive signaturepreventprospectivequantitative imagingresponserheumatologiststandard caresuccesstranscriptome sequencingtranslational studytreatment optimizationtreatment responsetreatment strategy
项目摘要
PROJECT SUMMARY
Pediatric chronic non-infectious uveitis (NIU) is an inflammatory ocular disease that has a substantial risk for
sight-threatening complications. Methotrexate (MTX) is the preferred first line systemic treatment for all subtypes
of NIU given its overall safety and affordability. However, MTX failure is as high as 50%. Biologic drugs are
reserved for those who fail MTX. The long delays waiting for therapeutic effect leads to prolonged glucocorticoid
use and continued accrual of ocular damage. As MTX may not be the appropriate first line treatment for all
subtypes of NIU, identifying predictors of MTX responsiveness will allow expeditious initiation of biologic
therapies. Our long-term goal is to prevent sight-threatening damage in children with NIU by initiating early
effective treatment that controls inflammation quickly.
This investigation is a longitudinal translational study that is a collaborative effort consisting of experts in
rheumatology, ophthalmology, ocular imaging, immunology and biostatistics. The objectives of this study are: 1)
To identify baseline demographic, clinical, laboratory, and imaging features in children with NIU that correlate
with response to MTX; 2) To assess the value of adding quantitative imaging modalities to monitor response to
MTX in children with NIU; and 3) To discover gene expression signatures that predict response and non-
response to MTX in children with NIU. A total of 120 children who are starting MTX for NIU will be enrolled in all
aims and followed prospectively at 3 and 6 months. Children will undergo serial clinical ophthalmic examinations
and imaging by anterior segment optical coherence tomography (AS-OCT), ultrawide field fluorescein
angiography (UWFFA), and OCT to assess MTX response. Aim 1 will identify the combination of variables at
baseline that predict a patient’s risk of response by 6 months. Aim 2 will assess the use of quantitative imaging
to evaluate and monitor MTX response over 6 months. These modalities will also be compared to the clinical
examination. In Aim 3, 20 pediatric non-uveitic controls will also be included. This aim is designed to discover
gene expression signatures that are associated with clinical and imaging based MTX response and non-
response. The success of this study will 1) optimize treatment of children with NIU by allowing earlier initiation
of biologics in those unlikely to respond to MTX, 2) demonstrate the clinical usefulness of quantitative imaging
in therapeutic decision-making, and 3) eventually shift the current treatment standard of NIU leading to improved
ocular health of children.
项目摘要
小儿慢性非感染葡萄膜炎(NIU)是一种炎症性眼疾病,具有很大的风险
危及视力并发症。甲氨蝶呤(MTX)是所有亚型的首选第一线系统治疗
NIU的总体安全性和负担能力。但是,MTX失败高达50%。生物药物是
保留给失败MTX的人。等待治疗效果的长延迟导致长期糖皮质激素
使用并继续口音眼损伤。因为MTX可能不是所有人的合适第一行处理
NIU的子类型,确定MTX响应能力的预测因子将允许迅速的生物学倡议
疗法。我们的长期目标是通过提早开始,以防止NIU儿童的视力危害
有效控制注射的有效治疗方法。
这项投资是一项纵向翻译研究,是一项合作努力,由专家组成
风湿病学,眼科,眼部成像,免疫学和生物统计学。这项研究的目标是:1)
确定NIU儿童的基线人口统计学,临床,实验室和成像特征
对MTX的响应; 2)评估添加定量成像方式的价值以监视对
NIU儿童的MTX; 3)发现基因表达特征,以预测反应和非 -
NIU儿童对MTX的反应。总共有120名开始MTX的儿童将参加所有人
目标并在3个月和6个月中前瞻性。儿童将接受连续临床眼科检查
和前段光学相干断层扫描(AS-OCT),超消极场荧光素的成像
血管造影(UWFFA)和OCT评估MTX响应。 AIM 1将确定变量的组合
基线可以预测患者的反应风险6个月。 AIM 2将评估定量成像的使用
在6个月内评估和监视MTX响应。这些方式也将与临床进行比较
考试。在AIM 3中,还将包括20个儿科非割草机控制。这个目标旨在发现
与基于临床和成像的MTX反应和非 - 非基因表达特征
回复。这项研究的成功将通过允许较早的启动来优化NIU儿童的治疗
生物制剂中不太可能响应MTX的生物制剂,2)证明了定量成像的临床实用性
在热决策中,以及3)最终改变了NIU的当前治疗标准,从而改善了
儿童的眼部健康。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sheila Therese Angeles-Han其他文献
Sheila Therese Angeles-Han的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sheila Therese Angeles-Han', 18)}}的其他基金
Predicting uveitis onset in children with juvenile idiopathic arthritis
预测幼年特发性关节炎儿童葡萄膜炎的发病
- 批准号:
10210401 - 财政年份:2019
- 资助金额:
$ 65.75万 - 项目类别:
Predicting uveitis onset in children with juvenile idiopathic arthritis
预测幼年特发性关节炎儿童葡萄膜炎的发病
- 批准号:
10018875 - 财政年份:2019
- 资助金额:
$ 65.75万 - 项目类别:
Predicting uveitis onset in children with juvenile idiopathic arthritis
预测幼年特发性关节炎儿童葡萄膜炎的发病
- 批准号:
10445255 - 财政年份:2019
- 资助金额:
$ 65.75万 - 项目类别:
Predicting uveitis onset in children with juvenile idiopathic arthritis
预测幼年特发性关节炎儿童葡萄膜炎的发病
- 批准号:
10661602 - 财政年份:2019
- 资助金额:
$ 65.75万 - 项目类别:
Outcomes of children with juvenile idiopathic arthritis-associated uveitis
幼年特发性关节炎相关葡萄膜炎儿童的结局
- 批准号:
9434093 - 财政年份:2017
- 资助金额:
$ 65.75万 - 项目类别:
Outcomes of children with juvenile idiopathic arthritis-associated uveitis
幼年特发性关节炎相关葡萄膜炎儿童的结局
- 批准号:
8310928 - 财政年份:2011
- 资助金额:
$ 65.75万 - 项目类别:
Outcomes of children with juvenile idiopathic arthritis-associated uveitis
幼年特发性关节炎相关葡萄膜炎儿童的结局
- 批准号:
8523893 - 财政年份:2011
- 资助金额:
$ 65.75万 - 项目类别:
Outcomes of children with juvenile idiopathic arthritis-associated uveitis
幼年特发性关节炎相关葡萄膜炎儿童的结局
- 批准号:
8913977 - 财政年份:2011
- 资助金额:
$ 65.75万 - 项目类别:
Outcomes of children with juvenile idiopathic arthritis-associated uveitis
幼年特发性关节炎相关葡萄膜炎儿童的结局
- 批准号:
8719114 - 财政年份:2011
- 资助金额:
$ 65.75万 - 项目类别:
Outcomes of children with juvenile idiopathic arthritis-associated uveitis
幼年特发性关节炎相关葡萄膜炎儿童的结局
- 批准号:
8165651 - 财政年份:2011
- 资助金额:
$ 65.75万 - 项目类别:
相似国自然基金
大豆疫霉前纤维蛋白PsPFN的功能、结构及其与PsORP1互作的生物学意义研究
- 批准号:32372602
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
滴灌用劣质水泵前微压过滤器物理-生物堵塞特性及诱发机制研究
- 批准号:52369013
- 批准年份:2023
- 资助金额:33 万元
- 项目类别:地区科学基金项目
酶促自组装与生物正交反应协同作用实现线粒体原位激活前药的研究
- 批准号:22304188
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于微生物代谢特征差异的城市尾水受纳水体亚硝胺前体物生成和迁移转化机制研究
- 批准号:52300200
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
肠道PEPT1靶向的程序化生物激活的帕拉米韦巯基二肽新型口服前药的研究
- 批准号:82360705
- 批准年份:2023
- 资助金额:31 万元
- 项目类别:地区科学基金项目
相似海外基金
Massage for GAD: Neuroimaging and clinical correlates of response
广泛性焦虑症的按摩:神经影像学和反应的临床相关性
- 批准号:
10665241 - 财政年份:2023
- 资助金额:
$ 65.75万 - 项目类别:
Using Functional Neuroimaging and Smartphone Digital Phenotyping to Understand the Emergence of Internalizing Illness
使用功能神经影像和智能手机数字表型来了解内化疾病的出现
- 批准号:
10749114 - 财政年份:2023
- 资助金额:
$ 65.75万 - 项目类别:
Gene regulatory networks in early lung epithelial cell fate decisions
早期肺上皮细胞命运决定中的基因调控网络
- 批准号:
10587615 - 财政年份:2023
- 资助金额:
$ 65.75万 - 项目类别:
Formation of a functional tendon enthesis during development and healing
在发育和愈合过程中形成功能性肌腱附着点
- 批准号:
10587399 - 财政年份:2023
- 资助金额:
$ 65.75万 - 项目类别:
Connected Language and Speech Along the Spectrum of Alzheimer’s Disease and Related Dementias: Digital Assessment and Monitoring.
阿尔茨海默病和相关痴呆症范围内的互联语言和言语:数字评估和监测。
- 批准号:
10662754 - 财政年份:2023
- 资助金额:
$ 65.75万 - 项目类别: